Epileptic Peripartum and Postpartum Seizure Frequency Unchanged by Pregnancy


The percentage of women who had ≥1 change in an antiepileptic drug dose or an overall dose increase during pregnancy and a decrease in dose during the postpartum period was higher among pregnant women than controls.

Page B. Pennell, MD

Data from a study published in the New England Journal of Medicine demonstrate a similar percentage between pregnant and nonpregnant women with epilepsy in terms of the increased seizure frequency in the peripartum period as compared to postpartum.

The findings also showed that changes in doses of antiepileptic drugs occurred more frequently in pregnant women than in nonpregnant women during similar time periods. At the end of the study period, 14% of pregnant women reported a decrease in seizure frequency compared to 11% of controls.

Lead author Page B. Pennell, MD, professor of neurology, Harvard Medical school; director of research, division of epilepsy, Brigham and Women’s Hospital, and colleagues aimed to compare the changes in seizure frequency and antiepileptic therapy through a prospective, observational, multicenter cohort study.

There were 351 pregnant women and 109 controls with epilepsy enrolled. In total, 70 of the 299 (23%) pregnant women and 23 of the 93 controls (25%) who had a history of impaired seizures and who had available data for the 2 epochs experienced higher seizure frequency during epoch 1 than during epoch 2 (odds ratio [OR], 0.93; 95% CI, 0.54–1.60).

Despite this, the distribution of the seizure frequency in epoch 1 as compared with epoch 2 was similar in the 2 groups within trimesters and according to seizure type, which included convulsive, focal, generalized, unclassified, and any type.

READ MORE: REM Not Correlated With Increased Risk of SUDEP

"Previous studies have suggested that seizures may increase during certain trimesters of pregnancy or during the peripartum period, but we did not find differences between the pregnant women and controls according to pregnancy stage or seizure type, including convulsive seizures,” Pennell et al wrote.

During epoch 1, at least 1 seizure that impaired awareness was reported in 87 of 299 pregnant women (29%) and in 29 of 93 controls (31%). Following that, there were 78 of the 299 pregnant women (26%) and 14 of 93 controls (15%) who reported at least 1 such seizure during epoch 2. When normalizing the mean frequency of seizures that impaired awareness to a 28-day value, Pennell and colleagues recorded 0.69 seizures in epoch 1 and 0.55 seizures in epoch 2 among pregnant women and 1.40 and 0.28 seizures, respectively, among nonpregnant women.

The investigators of the study also compiled changes in the doses of antiepileptic drugs that were administered in the 2 groups during the first 9 months of epoch 1. Changing the dose of an antiepileptic drug occurred at least once in 74% of pregnant women and in 31% of controls (OR, 636; 95% CI, 3.82–10.59).

In 209 of 299 pregnant women (70%), the dose of an antiepileptic drug was higher by the end of pregnancy compared to an increase in 22 of 93 controls (24%) during the corresponding periods (OR, 7.49; 95% CI, 4.37–12.84).

Lamotrigine was among the most used antiepileptic drug, with 101 pregnant women (33%) and 30 controls (32%) taking the monotherapy. Other monotherapies used included levetiracetam, carbamazepine, oxcarbazepine, zonisamide, and other.

After using risk-factor models to calculate a higher frequency of seizures in epoch 1 than in epoch 2, the OR for being seizure-free during the 9 months before pregnancy or enrollment was 0.22 (95% CI, 0.12–0.41). These models adjusted for seizure type, antiepileptic drug category and group, presence of catamenial epilepsy, mother’s IQ, and age.

Pennell and colleagues did not find any differences in the risk of an increased frequency of seizures among seizure types or drug categories or between groups in unadjusted and adjusted models.

Pennell PB, French JA, May RC, et al. Changes in seizure frequency and antiepileptic therapy during pregnancy. N Engl J Med. Published December 24, 2020. doi: 10.1056/NEJMoa2008663
Related Videos
Ro'ee Gilron, PhD
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.